Dr. Reddy's Laboratories announced that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories Inc., concluding that lndivior had not shown that it is likely
to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305. This decision vacates the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version
of Suboxone (buprenorphine and naloxone) sublingual film. As a result of the ruling, Dr. Reddy's will resume its launch activities as soon as permitted.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
